Crown ethers reverse P-glycoprotein-mediated multidrug resistance in cancer cells

• Published in: Scientific reports 2018-09, Vol.8 (1), p.14467-14, Article 14467
• Main Authors: Guberović, Iva, Marjanović, Marko, Mioč, Marija, Ester, Katja, Martin-Kleiner, Irena, Šumanovac Ramljak, Tatjana, Mlinarić-Majerski, Kata, Kralj, Marijeta
• Format: Article
• Language: English
• Subjects: 13; 13/106; 13/2; 13/31; 14; 14/34; 14/63; 631/67/1059/2326; 631/92/609; 82; 82/80; 96; 96/1; Cancer; Ethers; Glycoproteins; Humanities and Social Sciences; Ionophores; multidisciplinary; Multidrug resistance; Multidrug resistant organisms; P-Glycoprotein; Paclitaxel; Phenotypes; Potassium; Salinomycin; Science; Science (multidisciplinary); Tumors; Verapamil
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-32770-y

Multidrug resistance (MDR) is a widespread phenomenon exhibited by many cancers and represents a fundamental obstacle for successful cancer treatments. Tumour cells commonly achieve MDR phenotype through overexpression and/or increased activity of ABC transporters. P-glycoprotein transporter (P-gp, ABCB1) is a major cause of MDR and therefore represents a valuable target for MDR reversal. Several naturally occurring potassium ionophores (e.g. salinomycin) were shown to inhibit P-gp effectively. We have previously shown antitumour activity of a number of 18-crown-6 ether compounds that transport potassium ions across membranes. Here we present data on P-gp inhibitory activity of 16 adamantane-substituted monoaza- and diaza-18-crown-6 ether compounds, and their effect on MDR reversal in model cell lines. We show that crown ether activity depends on their lipophilicity as well as on the linker to adamantane moiety. The most active crown ethers were shown to be more effective in sensitising MDR cells to paclitaxel and adriamycin than verapamil, a well-known P-gp inhibitor. Altogether our data demonstrate a novel use of crown ethers for inhibition of P-gp and reversal of MDR phenotype.